Literature DB >> 29367108

Thymoquinone activates MAPK pathway in hippocampus of streptozotocin-treated rat model.

Tugce Dalli1, Merve Beker1, Sule Terzioglu-Usak1, Fahri Akbas1, Birsen Elibol2.   

Abstract

Streptozotocin (STZ), a glucosamine-nitrosourea compound, produces deficiencies in learning, memory, and cognitive functions when it was administered intracerebroventricularly (i.c.v). In molecular level, increase in neuroinflammation and oxidative stress in brain, and decrease in the number of surviving neurons are the outcomes of STZ administration. Herein, we aimed to investigate the effect of thymoquinone (TQ), an anti-inflammatory, immunomodulatory and neuroprotective agent, on STZ-induced neurodegeneration in rats. For this purpose, bilateral i.c.v. injection of STZ (3 mg/kg) was given to adult female rats on days 1 and 3. TQ (20 mg/kg/day in cornoil) was administered intragastrically to rats for 15 days starting from the 15th day of STZ injection. The Morris water maze test and passive avoidance test were applied to measure the learning and memory performance of animals. Following the behavioral tests, all of the rats were sacrificed for evaluation of molecular alterations. Rats in the STZ-TQ group showed higher performance in passive avoidance test than rats in the STZ group whose memory performance declined compared to control group. The worse memory performance in STZ group was correlated with low number of surviving neurons and high number of degenerating neurons. In addition, an increase in APOE expression and a decrease in NGF expression were observed with STZ injection. Administration of TQ reversed these STZ-triggered cognitive and molecular alterations. In the present study, we observed the neuroregenerative effects of TQ by activation of JNK protein, upregulation of mir-124, and downregulation of ERK1/2 and NOS enzymes. The same ameliorative effect of TQ was also observed in the pTau protein expression. To sum up, we can say that the healing effect of TQ on STZ induced neurodegeneration opens a new door for the development of Alzheimer's disease treatment using natural products as an adjuvant when their action mechanism was explained in detail.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Hippocampus; MAPK; Streptozotocin; Thymoquinone

Mesh:

Substances:

Year:  2018        PMID: 29367108     DOI: 10.1016/j.biopha.2018.01.047

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Sex-Independent Cognition Improvement in Response to Kaempferol in the Model of Sporadic Alzheimer's Disease.

Authors:  Parvin Babaei; Kimia Eyvani; Somayeh Kouhestani
Journal:  Neurochem Res       Date:  2021-03-12       Impact factor: 3.996

Review 2.  Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer's disease.

Authors:  Fabiha Zaheen Khan; Md Shaki Mostaid; Mohd Nazmul Hasan Apu
Journal:  Heliyon       Date:  2022-07-05

3.  Effect of Restraint Stress on Plasma PTH Concentration and Its Molecular Targets Expressions in Wistar Rats.

Authors:  Sule Terzioglu-Usak; Birsen Elibol; Tugce Dalli; Cansu Guler; Erhan Aysan
Journal:  Int J Endocrinol Metab       Date:  2018-09-17

Review 4.  Thymoquinone in Ocular Neurodegeneration: Modulation of Pathological Mechanisms via Multiple Pathways.

Authors:  Nur Musfirah Mahmud; Luminita Paraoan; Nurliza Khaliddin; Tengku Ain Kamalden
Journal:  Front Cell Neurosci       Date:  2022-03-02       Impact factor: 5.505

Review 5.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.